Monday , 6 February 2023

Method development and validation for the simultaneous estimation of Talazoparib and Pitavastatin in bulk and tablet dosage form by using RP-HPLC in biorelevant dissolution media

Agaiah Goud Bairi*1, Parameshwar Aleti2
1Department of Pharmaceutics, SRR College of Pharmaceutical Sciences, Elkathurthi, Telangana, India

2Department of Pharmaceutical Analysis, SRR College of Pharmaceutical Sciences, Elkathurthi, Telangana, India

The primary purpose of current study is to establish and validate a unique, specific, precise, fast and economic stability – suggesting an isocratic opposite liquid chromatoographic approach in large-scale and commercialised formulations for the quantitative measurement of Talazoparib. An estimation of medication for this pharmacological dose is provided with a cellular composition section Methanol: Acetate Buffer (ph-four.2) (40: 60 v/v) when completed with the Inertsil ODS (4.6mmx250mm, 5μm) when it is stored on the temperature of 35°C.The flow rate was replaced by ml/min, the effluents were monitored by a PDA-detector at a wavelength of 225 nm. Talazoparib retention time was established accordingly at 3.622min. With the ICH recommendations for excellent analytical parameters, validation of the method is steadily accomplished. The procedure for Talazoparib was shown to be linear in a range of 60-140μg/ml. The established approach has shown to be replicable at a percent RSD price for good purchases well below 2 for centred strength and precision. Assessment of a modified commercial approach and find for Talazoparib by ninety-nine.5%. For the approximation of pitavastatin in substance & medicine dose structures, an honest, clear, thorough, and precise turn around RP-HPLC was created and agreed. The symmetry ODS C18 (4,6 D250MM, 5μm) section using PDA discovery at 235 nm was completed with chromatographic partition of Pitavastatin. Methanol: Phosphate Buffer (35:65) v/v was the enhanced portable stage.  The rate of flow was 1ml/min. At a maintenance time of 2.572 minutes. Chromatogram demonstrated the basic top. The approach is designed for linearity, precision, accuracy, location, measuring breaking point, heart rate and strength. The linearity was derived from the 6-14μg/ml focus range. The coefficient of regression was 0.999. Y=12035x–6630 was seen in the reciprocal situation. For the approximation of Pitavastatin, the most discovery and breaking point were found independently in 1.2μg/ml and 3.6μg/ml. Pitavastatin recovery was observed to be within the range of 100.72%. For quantifiable Pitavastatin assurance in bulk and pharmacological measurement structures, a proposed approach has been effectively used.

Keywords: Talazoparib, Pitavastatin, RP-HPLC

Scroll To Top